Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

OBJECTIVE: We investigated the mechanistic and pharmacological properties of anifrolumab, a fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal antibody in development for SLE. METHODS: IFNAR1 surface expression and internalisation on human monocytes before...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lupus Sci Med
Autors principals: Riggs, Jeffrey M, Hanna, Richard N, Rajan, Bhargavi, Zerrouki, Kamelia, Karnell, Jodi L, Sagar, Divya, Vainshtein, Inna, Farmer, Erika, Rosenthal, Kimberly, Morehouse, Chris, de los Reyes, Melissa, Schifferli, Kevin, Liang, Meina, Sanjuan, Miguel A, Sims, Gary P, Kolbeck, Roland
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2018
Matèries:
Clinical Trials and Drug Discovery
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5890856/
https://ncbi.nlm.nih.gov/pubmed/29644082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2018-000261
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars